SMTL ID : 9f6c.2 (1 other biounit)

Cardiac myosin motor domain in the pre-powerstroke state co-crystallized with the inhibitor aficamten

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.33 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 4 residues within 4Å: Chain A: T.185, S.242 Ligands: ADP.3, VO4.4 4 PLIP interactions: 2 interactions with chain A, 2 Ligand-Water interactions Metal complexes: A:T.185, A:S.242, H2O.1, H2O.1

1 x 6I6: aficamten(Non-covalent)

6I6.2: 20 residues within 4Å: Chain A: R.243, F.244, G.245, Y.266, L.267, L.268, E.269, K.270, I.462, A.463, F.473, E.474, C.477, I.478, T.481, V.647, H.651, N.654, L.655, L.658 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:Y.266, A:Y.266, A:L.267, A:E.269, A:A.463, A:I.478, A:I.478, A:T.481, A:N.654, A:L.655, A:L.658 Hydrogen bonds: A:L.267, A:A.463, A:T.481

1 x ADP: ADENOSINE-5'-DIPHOSPHATE(Non-covalent)

ADP.3: 19 residues within 4Å: Chain A: I.114, N.126, P.127, Y.128, K.129, Y.134, E.179, S.180, G.181, A.182, G.183, K.184, T.185, V.186, N.238, N.240, S.242 Ligands: MG.1, VO4.4 17 PLIP interactions: 17 interactions with chain A Hydrogen bonds: A:N.126, A:Y.134, A:Y.134, A:G.181, A:A.182, A:G.183, A:K.184, A:T.185, A:V.186, A:N.238, A:S.242 Water bridges: A:N.187, A:N.187, A:N.240, A:N.240, A:S.242 Salt bridges: A:K.184

1 x VO4: VANADATE ION(Non-covalent)

VO4.4: 10 residues within 4Å: Chain A: S.180, G.181, K.184, N.238, S.241, S.242, A.463, G.464 Ligands: MG.1, ADP.3 8 PLIP interactions: 8 interactions with chain A Hydrogen bonds: A:G.181, A:K.184, A:T.185, A:N.238, A:S.241, A:S.242, A:S.242, A:G.464

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hartman, J.J. et al., Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res (2024)

Release Date

2024-09-04

Peptides

Myosin-7: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Myosin-7

Related Entries With Identical Sequence